Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.
Key facts
- Where
- Barcelona, SpainSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 80 years old?
Source: NCT07652892, who can take part
Where in Spain
- Hospital de la Santa Creu i Sant PauBarcelona, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Trial code
- NCT07652892
- Record updated
- 17 June 2026
- Original description
The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.Read full original descriptionShow less
IIBSP-MAS-2025-133
The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.
Inclusion: Patients will be included who are able to provide informed consent and actively participate in periodic assessments.
Exclusion: Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.); Advanced neurodegenerative diseases or severe psychiatric disorders; Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease; Risky alcohol consumption:; > 30 g/day in men and > 20 g/day in women. AUDIT score: > 7 points in men, > 5 in women.